



Lipid management for patients with CVD and risks of CVD

Primary prevention

Atorvastatin 40mg

Patients with:
CKD 3 and above (regardless of cholesterol level or risk of CVD)
aim for cholesterol <4mmol/l with up-titration to 80mg
Atorvastatin if required

QRISK2>10% 10 year Cardiovascular Risk

Diabetes Type 1

- who are older than 40 or
- nephropathy or
- had DM for more than 10 years or
- other CVD risk factors

Diabetes Type 2 aim for cholesterol <4mmol/l with up-titration to 80mg Atorvastatin if required

Secondary prevention

Atorvastatin 80mg

Patients with:
established CVD
CHD, Stroke & TIA, PAD

Before starting lipid
modification therapy take full
lipid profile

Repeat lipid profile after 3
months and never after if not
indicated

Before starting lipid
modification therapy take full
lipid profile

Repeat lipid profile after 3
months and never after if not
indicated

Be aware of

- Familial Hyperlipidaemia in anyone with a cholesterol >7.5mmol/l
- Persistent Triglyceride levels >10
- End stage renal disease
- Consider Diabetes e-consultation or Renal e-consultation in these cases

This guide was developed and agreed with:

- Dr John Stoves - Consultant in renal medicine
- Dr Steven Lindsay - Consultant cardiologist
- Dr Chris Patterson – Consultant in stroke medicine
- Mr Kevin Mercer - Consultant vascular surgeon
- Dr Chris Harris - GP lead Bradford's Healthy Hearts programme
- Dr Youssef Beaini - GP and GPwSI cardiology
- Mr Greg Fell - Public Health Consultant
- Dr Donald Whitelaw - Consultant in diabetes